SVCM
NMRA icon

Saturn V Capital Management’s Neumora Therapeutics NMRA Stock Holding History

Saturn V Capital Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-432,996
Closed -$5.72M – 27
2024
Q3 		$5.72M Buy
432,996
+42,912
+11% +$501K 2.04% 18
2024
Q2 		$3.83M Buy
+390,084
New +$4.04M 1.45% 21

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Saturn V Capital Management's NMRA Position: Q4 2024 in Review

Saturn V Capital Management sold out of Neumora Therapeutics (NMRA) in Q4 2024, closing a stake of 432,996 shares — an estimated $5.72M sold.

Saturn V Capital Management first reported a position in NMRA in Q2 2024 and held it in 2 quarters. The position peaked at $5.72M in Q3 2024. 134 funds tracked by Wall St. Rank hold NMRA as of Q4 2024.

  • Saturn V Capital Management reported no remaining Neumora Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Saturn V Capital Management sold 432,996 Neumora Therapeutics shares in Q4 2024, an estimated $5.72M.
  • Saturn V Capital Management first reported a position in Neumora Therapeutics in Q2 2024 and held it in 2 quarters.
  • Saturn V Capital Management's Neumora Therapeutics position peaked at $5.72M in Q3 2024.
  • 134 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2024.

Based on Saturn V Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.